Ipsen’s rare disease drug palovarotene knocked back in EU
pharmaphorum
JANUARY 27, 2023
The decision comes after Ipsen was forced to withdraw its marketing application for palovarotene in the US in 2021, which delayed regulatory filings elsewhere, although the French pharma company has picked up an approval for the drug in Canada, where it is sold as Sohonos.
Let's personalize your content